 Keros Therapeutics, Inc. Keros or the Company KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that the Company is set to join the Russell 2000 Index, effective after the close of the U.S. markets on June 26, 2020. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe. 